IGGENIX
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
IGGENIX
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2019-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.iggenix.com
Total Employee:
1+
Status:
Active
Contact:
+1 650 491 9626
Email Addresses:
[email protected]
Total Funding:
35 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt WordPress Nginx Google Apps For Business Google Maps Microsoft Azure DNS
Similar Organizations
Arima Genomics
Arima Genomics is a biotechnology company that develops solutions to drive genomics discovery.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Ocean Biomedical
Ocean Biomedical is a biotechnology company that accelerates new discoveries in the world of medicine.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Rapid Novor
Rapid Novor is a biotech company dedicated to advance next-generation protein sequencing technology.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Sojournix
Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Global Brain Corporation
Global Brain Corporation investment in Series A - IgGenix
AllerFund
AllerFund investment in Series A - IgGenix
Shangbay Capital
Shangbay Capital investment in Series A - IgGenix
Alexandria Venture Investments
Alexandria Venture Investments investment in Series A - IgGenix
Khosla Ventures
Khosla Ventures investment in Series A - IgGenix
Mattias Westman
Mattias Westman investment in Series A - IgGenix
Khosla Ventures
Khosla Ventures investment in Series A - IgGenix
Parker Ventures
Parker Ventures investment in Series A - IgGenix
Official Site Inspections
http://www.iggenix.com Semrush global rank: 8.75 M Semrush visits lastest month: 261
- Host name: 45.108.229.35.bc.googleusercontent.com
- IP address: 35.229.108.45
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "IgGenix"
IgGenix
IgGenix is a clinical-stage antibody discovery and development company with a mission to solve allergies and other immunological diseases. We believe we can empower people to live life …See details»
IgGenix - Crunchbase Company Profile & Funding
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. …See details»
IgGenix 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for IgGenix. Use the PitchBook Platform to explore the full profile.See details»
Iggenix, Inc. Company Profile | South San Francisco, CA
Find company research, competitor information, contact details & financial data for Iggenix, Inc. of South San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
IgGenix: Contact Details, Revenue, Funding, Employees and …
IgGenix, a clinical-stage biotech company founded on innovations from Stanford’s Steve Quake and allergy expert Kari Nadeau, seeks motivated, organized individuals to join its South San …See details»
IgGenix - Funding, Financials, Valuation & Investors - Crunchbase
IgGenix is funded by 9 investors. Alexandria Venture Investments and Khosla Ventures are the most recent investors.See details»
IgGenix - Contacts, Employees, Board Members, Advisors & Alumni
IgGenix has 6 current employee profiles, including Chief Executive Officer Jessica Grossman. IgGenix has 3 board members and advisors, including Joel Marcus.IgGenix is a biotechnology …See details»
IgGenix - Products, Competitors, Financials, Employees, …
About IgGenix IgGenix is a biotechnology company focused on developing first-in-class therapies for allergic diseases. The company leverages its SEQ SIFTER™ antibody discovery platform …See details»
IgGenix Announces Jessica Grossman, M.D., as Chief Executive …
Jun 24, 2021 Prior to joining IgGenix, Dr. Grossman served as CEO of Medicines360, a commercial stage pharmaceutical organization working to advance clinical research in …See details»
IgGenix Company Profile - Office Locations, Competitors ... - Craft
IgGenix has 5 employees at their 1 location and $35 m in total funding,. See insights on IgGenix including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
IgGenix, Inc Overview | SignalHire Company Profile
IgGenix, Inc is a private company that has been in the industry for 4 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the CEO is occupied by …See details»
IgGenix - VentureRadar
VentureRadar Research / Company Website Dansk Biotek DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for …See details»
IgGenix Announces Move of Headquarters to Lilly Gateway Labs in …
Apr 28, 2022 IgGenix joins 8 other leading biotechnology companies in the South San Francisco Gateway Labs. “The purpose of the Lilly Gateway Labs is to offer emerging biotech companies …See details»
IgGenix - Crunchbase
IgGenix, Long Bridge Medical, Novellus, Red Queen Therapeutics, ChitogenX, and Remix Therapeutics are all part of the biotechnology industry. Long Bridge Medical, Red Queen …See details»
IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody …
IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody Discovery at 2025 AAAAI / WAO Joint Congress Data highlight potential for new diagnostics and therapeutics targeting red …See details»
The End of Food Allergy by Kari Nadeau MD, PhD and Sloan Barnett
IgGenix At IgGenix, our mission is to develop a first-in-class therapy for millions of people whose daily lives are limited by food allergies and other severe allergic conditions. Starting from a …See details»
Global Brain has invested in IgGenix, Inc., a biotech startup ...
Apr 18, 2022 Global Brain has invested in IgGenix, Inc. (IgGenix), a biotech startup developing antibody drugs for food and environmental allergies, through its GB-VII Growth Fund …See details»
IgGenix Announces First Close of $40M Series B Financing to …
Feb 6, 2023 SOUTH SAN FRANCISCO, Calif. – February 6th, 2023 – IgGenix, Inc., a pre-clinical biotechnology company taking a revolutionary approach to directly address allergic …See details»
IgGenix: antibody engineering for food allergies - BioCentury
Nov 7, 2020 IgGenix is pairing single-cell sequencing with antibody engineering to create a new class of food allergy therapies that selectively suppresses allergen-triggered immunity while …See details»
IgGenix Announces $25M in Series A1 Funding – IgGenix
Jul 27, 2021 IgGenix Announces $25M in Series A1 Funding Financing Will Support the Biotechnology Company in Expanding Its Discovery Platform in Allergic Disease While …See details»